Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma
This is a Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Decitabine
maximum tolerated dose, The primary endpoint for the phase I portion of the study is to determine the maximum tolerated dose of Decitabine when given in combination with a standard dose (q21 day) regimen of R-CHOP in patients with DLBCL., day1 to 21|complete response rate, The primary endpoint for the phase II portion of the study will be complete response rate., 21 days after 6 cycles of treatment (each cycle is 21 days)
Overall response rate, 21 days after 6 cycles of treatment (each cycle is 21 days)|Event-free survival, 2 years|Overall survival, 2 years|Progression-free survival, 2 years|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Up to 30 days after completion of study treatment
This is a Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma